Treatment of Lipodystrophy with Troglitazone
Authors: Elif Arioglu, Simeon I. Taylor
Journal: Annals of Internal Medicine (2001)

Letters19 June 2001Treatment of Lipodystrophy with TroglitazoneElif Arioglu, MD and Simeon I. Taylor, MD, PhDElif Arioglu, MDNational Institute of Diabetes and Digestive and Kidney Diseases, Diabetes Branch; Bethesda, MD 20892-1829 (Arioglu, Taylor)Search for more papers by this author and Simeon I. Taylor, MD, PhDNational Institute of Diabetes and Digestive and Kidney Diseases, Diabetes Branch; Bethesda, MD 20892-1829 (Arioglu, Taylor)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-12-200106190-00028 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:There are many unanswered questions about the relationship between insulin resistance and the distribution of body fat. Under most circumstances, increases in the content of visceral body fat are correlated with insulin resistance. Indeed, as noted by Dr. Cheng, a marked increase in visceral body fat has been reported in HIV-infected patients treated with highly active antiretroviral therapy, including protease inhibitors, and this abnormal fat distribution (HIV lipodystrophy) may be the cause of insulin resistance (1-3). The hyperinsulinemia seen in these patients is probably secondary, resulting from homeostatic mechanisms that attempt to compensate for the insulin resistance. The ...References1. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen T, Chevenne D, Capeau J, et al . Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab. 1999;25:225-32. [PMID: 10499191] MedlineGoogle Scholar2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm D, et al . A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-8. [PMID: 9619798] CrossrefMedlineGoogle Scholar3. Yanovski J, Miller K, Kino T, Friedman T, Chrousos G, Tsigos C, et al . Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab. 1999;84:1925-31. [PMID: 10372688] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: National Institute of Diabetes and Digestive and Kidney Diseases, Diabetes Branch; Bethesda, MD 20892-1829 (Arioglu, Taylor) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEfficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes Elif Arioglu , Jennifer Duncan-Morin , Nancy Sebring , Kristina I. Rother , Nicole Gottlieb , Jay Lieberman , David Herion , David E. Kleiner , James Reynolds , Ahalya Premkumar , Anne E. Sumner , Jay Hoofnagle , Marc L. Reitman , and Simeon I. Taylor Treatment of Lipodystrophy with Troglitazone Jose S. Cheng Metrics 19 June 2001Volume 134, Issue 12Page: 1153-1154KeywordsAdipogenesisAdipose tissueFatsGenetic diseasesHIVHyperinsulinemiaInsulin resistanceLipodystrophyLipogenesisProtease inhibitors ePublished: 19 June 2001 Issue Published: 19 June 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...